Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-11-07
1996-03-12
Dentz, Bernard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514216, 514278, 540477, 540582, 546 18, 546112, 546183, A61K 3144, C07D22122
Patent
active
054986141
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention relates to novel bridged aza-bicyclic derivatives as Substance receptor and related compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment and prevention of inflammatory and central nervous system disorders, as well as several other disorders. The pharmaceutically active compounds of this invention are substance receptor. This invention also relates to novel intermediates used in the synthesis of such substance receptor.
Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being named because of their prompt stimulatory action on smooth muscle tissue. More specifically, substance P is a pharmacologically active neuropeptide that is produced in mammals (having originally been isolated from gut) and possesses a characteristic amino acid sequence that is illustrated by D. F. Veber et al. in U.S. Pat. No. 4,680,283. The wide involvement of substance P and other tachykinins in the pathophysiology of numerous diseases has been amply demonstrated in the art. For instance, substance P has recently been shown to be involved in the transmission of pain or migraine (see B.E.B. Sandberg et al., Journal of Medicinal Chemistry, 25, 1009 (1982)), as well as in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory diseases such as asthma and rheumatoid arthritis, respectively, in rheumatic diseases such as fibrositis, and in gastrointestinal disorders and diseases of the GI tract such as ulcerative colitis and Crohn's disease, etc. (see D. Regoli in "Trends in Cluster Headache," edited by F. Sicuteri et al., Elsevier Scientific Publishers, Amsterdam, pp. 85-95 (1987)).
Attempts have been made to provide antagonists for substance P and other tachykinin peptides in order to more effectively treat the various disorders and diseases listed above. The few such antagonists thus far described are generally divided between peptide-like and non peptide-like in nature. Peptide-like antagonists are too labile from a metabolic point of view to serve as practical therapeutic agents in the treatment of disease. Non-peptidic antagonists of the present invention, on the other hand, do not possess this drawback, being far more stable from a metabolic point of view than the agents referred to above.
Quinuclidine derivatives and related compounds that exhibit activity as substance P receptor antagonists are referred to in PCT Patent Application PCT/US89/05338, filed Nov. 20, 1989, U.S. patent application Ser. No. 557,442 filed Jul. 23, 1990, PCT application PCT/US91/02853 filed on Apr. 25, 1991 PCT application PCT/US91/03369 filed on May 14, 1991.
Monocyclic piperdine compounds are referred to in European Patent Publication 0,436,334 published on Jul. 10, 1990.
Piperdine derivatives and related heterocyclic nitrogen containing compounds that are useful as substance receptor are referred to in U.S. patent application Ser. No. 590,423 filed Sep. 28, 1990, U.S. patent application Ser. No. 717,943 filed on Jun. 20, 1991, and U.S. patent application Ser. No. 724,268 filed Jul. 1, 1991. Non-peptidic antagonists have also been described in published European patent application 0436334.
SUMMARY OF THE INVENTION
The present invention relates to compounds of the formula ##STR2## wherein m is an integer from 0 to 8, and any one of the carbon-carbon single bonds of (CH.sub.2).sub.m may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said (CH.sub.2).sub.m may optionally be substituted with R.sup.8 ; (CH.sub.2).sub.z may optionally be substituted with R.sup.4 ; hydroxy, alkoxy or fluoro; branched alkyl, (C.sub.3 -C.sub.7)cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from phenyl, indanyl, and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazoly
REFERENCES:
patent: 3560510 (1971-02-01), Warawa et al.
patent: 4358446 (1982-11-01), Haken et al.
patent: 4552960 (1985-11-01), Krumkalns et al.
patent: 4680283 (1987-07-01), Veber et al.
patent: 5138060 (1992-08-01), Godek et al.
patent: 5162339 (1992-11-01), Lowe
E. J. Warawa et al., "Quinuclidine Chemistry", J. Med. Chem., 18, 587 (1975).
Sandberg et al., "Substance P", J. Med. Chem., 25, 1009, (1982).
P. J. Goadsby et al., "Release of Vasoactive Peptides", Ann. Neurol., 23, 193 (1988).
Regoli, "Neurokinin Agonists & Antagonists", Elsevier Scientific Publishers, Amsterdam, pp. 85-95 (1987).
L. S. Trifonov et al., "Synthesis of 1,2-Five-Ring-Annellated Barrelesnes", Halvetica Chimica Acta, 70, 4, 1732-1736 (1987).
A. S. Yanni et al., "Synthesis & Biological Activity", Indian J. Chem., 21B (7), 705-6, (1982).
Y. P. Gupta et al., "Synthesis of 2, 12-Diazachrysene via Benzene Cyclization Reaction", Indian J. Chem., 19B (5), 400-1, (1980).
V. N. Gogte et al., "Infrared Spectral Study of the Effect of Substitution on Conformation and Hydrogen Bonding in 3-(aryl-amino)propanols", Indian J. Chem., 17B (3), 230-2, (1979).
S. V. Kessar et al., "New Routes to Condensed Polynuclear Compounds", Tetrahedron, 29, Pergamon Press, (GB), 419-424 (1973).
G. N. Walker et al., "Synthesis of Carried Heterocyclic & Substituted Arylalkyl", J. Med. Chem., 9, No. 4, (1966), 624-630.
G. N. Walker et al., "Applicaiton of Sodium Borohydride", Journal of Organic Chemistry, 26, No. 8, (1961), American Chemical Society, (US), 2740-2747.
Suman Rakhit et al., "Formation of Animals form Amines via Pummerer Rearrangement", Can. J. Chem., 57, No. 10, 1153 (1979).
Butterfield Garth
Dentz Bernard
Ginsburg Paul H.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Bridged aza-bicyclic derivatives as substance P antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bridged aza-bicyclic derivatives as substance P antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bridged aza-bicyclic derivatives as substance P antagonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2100118